## Edgar Filing: Jazz Pharmaceuticals plc - Form 4

Jazz Pharmaceuticals plc Form 4 September 29, 2015

September 29,	2015									
<b>FORM</b> Check this	UNITED S							OMB Number:	PROVAL 3235-0287 January 31,	
if no longer subject to Section 16. Form 4 or Form 5 obligations	Filed purs	<b>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,					Expires: Estimated a burden hour response	ted average hours per		
See Instruction 1(b). See Instruction See Ins										
(Print or Type Res	sponses)									
MILLER MICHAEL PATRICK Symbol			I					Reporting Person(s) to		
(Last)	(First) (M		e of Earliest 7	•	-	<i>i</i> <b>z</b> -j	(Check	c all applicable	)	
			h/Day/Year)				Director       10% Owner         Officer (give title       Other (specify below)         SVP, US Commercial			
Filed(Mor			mendment, D Month/Day/Yea		al		<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
DUBLIN 4, L	.2						Person			
(City)	(State) (Z	Zip) T	able I - Non-	Derivative	Secur	ities Acqu	iired, Disposed of,	or Beneficiall	y Owned	
	•	2A. Deemed Execution Date, any (Month/Day/Yea	Code	4. Securi or(A) or Di (Instr. 3,	(A) or	l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Ordinary 0 Shares 0	9/25/2015		S <u>(1)</u>	100	D	\$ 145.23	13,890 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)			6. Date Exercisable and Expiration Date (Month/Day/Year)		Amou Under Secur	tle and unt of crlying rities r. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Repo	rting O	wners				Relation	nships				

## Edgar Filing: Jazz Pharmaceuticals plc - Form 4

<b>Reporting Owner Name / Address</b>	i controlisin po					
	Director	10% Owner	Officer	Other		
MILLER MICHAEL PATRICK CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4 DUBLIN 4, L2			SVP, US Commercial			
Signatures						
By: /s/ Karen Eberle as attorney in fact For: Michael Pat Miller	rick	09/2	8/2015			
<u>**</u> Signature of Reporting Person		Γ	Date			

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- (2) Includes 69 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.